Association Between Time in Range and Advanced Cardiovascular‐Kidney‐Metabolic Syndrome in Older Adults With Type 2 Diabetes Authors: Hang Su, Jiaying Ni, Jinghao Cai, Wei Zhu, Yufei Wang, Jian Zhou, Jingyi Lu, Xiaojing Ma Published: 2026 ABSTRACT ABSTRACTAimsCardiovascular, kidney and metabolic diseases are pathophysiologically interrelated and are conceptualised within the cardiovascular‐kidney‐metabolic (CKM) syndrome framework. However, evidence linking continuous glucose monitoring (CGM) to CKM syndrome remains limited. This study examined the association between time in range (TIR), the core CGM metric, and advanced CKM syndrome.Materials and MethodsA total of 2497 adults aged ≥ 60 years with type 2 diabetes were included. CKM syndrome was defined according to the American Heart Association Presidential Advisory, with stages 3–4 classified as advanced CKM syndrome.ResultsParticipants with advanced CKM syndrome exhibited significantly lower TIR levels than those with non‐advanced CKM syndrome (p < 0.001). After multivariable adjustment, each 1‐standard deviation decrease in TIR was independently associated with higher odds of advanced CKM syndrome (OR 1.28, 95% CI 1.16–1.42). Restricted cubic spline analyses demonstrated a linear inverse association between TIR and advanced CKM syndrome, with the estimated OR approaching unity at approximately 70%. The prevalence of advanced CKM syndrome increased progressively across TIR categories of > 70%, 50%–70% and ≤ 50% (p for trend < 0.001). Although TIR levels of 50%–70% exceed the currently recommended target of > 50% for older adults, this range remained associated with higher odds of advanced CKM syndrome compared with TIR > 70% (OR 1.40, 95% CI 1.12–1.75). Higher TIR was not associated with increased hypoglycemia exposure.ConclusionsLower TIR was associated with advanced CKM syndrome, supporting the potential value of CGM‐derived TIR in evaluating multisystem cardiovascular‐kidney‐metabolic burden in older adults with type 2 diabetes.Keywords: cardiovascular‐kidney‐metabolic syndrome, comorbidity, continuous glucose monitoring, older adults, time in range, type 2 diabetes Abbreviations body mass index continuous glucose monitoring cardiovascular‐kidney‐metabolic coefficient of variation dipeptidyl peptidase‐4 estimated glomerular filtration rate glucagon‐like peptide‐1 glycated haemoglobin A1c high‐density lipoprotein cholesterol integrated discrimination improvement low‐density lipoprotein cholesterol mean sensor glucose net reclassification improvement standard deviation sodium‐glucose cotransporter 2 time above range time below range time in range Introduction In 2023, the American Heart Association introduced cardiovascular‐kidney‐metabolic (CKM) syndrome as an integrated framework for the clinical management of metabolic, kidney and cardiovascular diseases [1, 2]. Within this framework, metabolic dysregulation is recognised as a major driver of cardiovascular and renal injury, positioning type 2 diabetes as a central condition. Type 2 diabetes lies between early metabolic risk factors and established multiorgan damage (advanced CKM stages 3–4) and its prognosis is generally unfavourable when multimorbidity is present [3, 4, 5]. Older adults account for a substantial proportion of individuals with CKM syndrome, with more than half reaching advanced stages [6, 7, 8]. Given the marked clinical heterogeneity, as well as the need to balance risks and benefits, diabetes care in this population continues to be a subject of debate. Continuous glucose monitoring (CGM) has revolutionised diabetes management over the past decade. Among CGM‐derived metrics, time in range (TIR; 70–180 mg/dL [3.9–10.0 mmol/L]) has emerged as a core measure of glycemic control and shows consistent associations with both microvascular and macrovascular complications [9, 10]. While current guidelines suggest a conservative TIR target of > 50% for older adults to minimise hypoglycemia risk [11], it remains unclear whether this threshold is sufficient in relation to CKM syndrome progression. As diabetes technologies advance, emerging concepts such as time in tight range (TITR) raise the possibility that setting higher glycemic goals may confer additional clinical benefits [11]. However, to our knowledge, no prior studies have evaluated CGM‐derived metrics within the integrated CKM framework. Therefore, our study aimed to investigate the association between glycemic control, assessed by CGM and advanced CKM syndrome in older adults with type 2 diabetes and to explore potential glycemic targets for this population. Research Design and Methods Study Population This cross‐sectional study was conducted using a protocol previously described in detail [9, 12]. Adults with type 2 diabetes who were hospitalised for routine evaluation of diabetic complications were consecutively recruited from the Department of Endocrinology and Metabolism at Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine between May 2020 and July 2023. Eligible participants were aged ≥ 60 years, with complete clinical data and a stable glucose‐lowering treatment regimen for the past 3 months. The following exclusion criteria were applied: presence of hyperosmolar hyperglycemic state or diabetic ketoacidosis at or shortly before hospitalisation; current systemic glucocorticoid therapy; active malignancy; severe psychiatric disorders; severe hepatic impairment. A total of 2497 participants with complete data for CKM syndrome classification were included in the analysis (Figure S1). The study protocol was approved by the Ethics Committee of Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants. Measurements After an overnight fast of at least 10 h, venous blood samples were obtained on the morning following hospital admission for the assessment of glycated haemoglobin A1c (HbA1c), lipid profiles, serum creatinine and other biochemical indicators. Laboratory measurements were conducted using standardised procedures [9, 12]. Albuminuria was assessed using the urinary albumin‐to‐creatinine ratio (UACR) from a spot urine sample. Urinary albumin was measured by an immunoturbidimetric assay. Serum creatinine was determined using the sarcosine oxidase method on a Hitachi 7600–120 autoanalyser (Hitachi, Tokyo, Japan). HbA1c was measured by high‐performance liquid chromatography (D‐100 Haemoglobin Testing System, Bio‐Rad Laboratories, Hercules, CA, USA). Demographic and clinical characteristics, including age, sex, smoking status, medical history and medication use, were extracted from electronic medical records. Cardiovascular conditions were identified from documented diagnoses, with available vascular imaging additionally considered for peripheral artery disease when applicable. Trained nurses measured height, weight and blood pressure according to standard protocols. The diagnosis of type 2 diabetes followed the 2010 American Diabetes Association (ADA) criteria [13]. Body mass index (BMI) was calculated as weight divided by height squared (kg/m2) and estimated glomerular filtration rate (eGFR) was derived from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD‐EPI) equation [14]. CGM Metrics All participants underwent continuous glucose monitoring for up to 7 days using a retrospective CGM system (iPro2, Medtronic, Northridge, CA, USA). This blinded system, which minimises potential interference from glucose feedback, recorded interstitial glucose concentrations at 5‐min intervals and was calibrated using capillary finger‐stick glucose measurements at least every 12 h (SureStep glucometer, LifeScan, Milpitas, CA, USA). For each participant, CGM data were used to calculate mean sensor glucose (MSG), glucose standard deviation (SD), coefficient of variation (CV) and mean amplitude of glycemic excursions (MAGE). Time‐based CGM metrics included the percentage of time within the range of 3.9–10.0 mmol/L (TIR, 70–180 mg/dL), within the tight range of 3.9–7.8 mmol/L (TITR, 70–140 mg/dL), as well as time above range > 10.0 mmol/L (TAR, > 180 mg/dL) and time below range < 3.9 mmol/L (TBR, < 70 mg/dL) [11]. Using the CGM time‐series data, a hypoglycemic episode was defined as sensor glucose < 3.9 mmol/L for at least 15 consecutive minutes and was considered resolved after sensor glucose returned to ≥ 3.9 mmol/L for at least 15 consecutive minutes [11]. During monitoring, participants followed a standardised diet (25 kcal/kg per day; 55% carbohydrate, 17% protein and 28% fat) while maintaining their usual treatment regimen. Definition of CKM Syndrome CKM staging was based on the 2023 American Heart Association Presidential Advisory [1, 15]. Stage 2 was defined by the presence of metabolic risk factors or moderate‐ to high‐risk chronic kidney disease. Stage 3 was characterised by subclinical cardiovascular disease or its risk equivalents. Stage 4 included individuals with established clinical cardiovascular disease, including coronary heart disease, heart failure, myocardial infarction, stroke, or peripheral artery disease. CKM stages 3–4 were considered advanced CKM syndrome and all other stages were considered non‐advanced CKM syndrome. Detailed criteria and rationale for CKM classification and staging are provided in Table S1. Statistical Analysis All statistical analyses were performed using R software (version 4.2.2). Normality of continuous variables was assessed prior to analysis. Participant characteristics are presented as medians with interquartile ranges (IQRs) or numbers (percentages). Group comparisons were conducted using the Wilcoxon rank‐sum test for continuous variables and the χ 2 test for categorical variables. We conducted multivariable logistic regression analyses to evaluate the associations of CGM‐derived metrics and HbA1c (per 1‐standard deviation change) with advanced CKM syndrome. Results are reported as odds ratios (ORs) with 95% confidence intervals (CIs). Regression models were adjusted for age, sex, diabetes duration and current smoking status based on prior literature [16, 17], without adjusting for variables included in the definition of CKM syndrome. Restricted cubic spline analyses were further applied to examine the relationship between TIR and advanced CKM syndrome. The discriminative performance of glycemic indicators for identifying advanced CKM syndrome was compared using the C‐statistic, integrated discrimination improvement (IDI) and net reclassification improvement (NRI). Cumulative distribution curves were used to illustrate the proportions of participants achieving candidate TIR thresholds in the overall population and across CKM stages. Hypoglycemia safety was assessed by examining TBR, achievement of the clinical target for hypoglycemia exposure (TBR < 1%) and hypoglycemic episodes across TIR categories. Subgroup analyses were conducted according to sex, age, BMI, eGFR and HbA1c level. Treatment‐related subgroups were additionally examined according to insulin use, sodium‐glucose cotransporter 2 (SGLT2) inhibitor use and glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) use and interaction terms were tested. To assess the robustness of the findings, sensitivity analyses included models further adjusted for medication use and analyses restricted to participants aged ≥ 65 years. For statistical testing, two‐sided p‐values < 0.05 were considered significant. Results Study Population Of the 2497 participants (median age, 67.0 years [64.0–72.0]; 53.4% male; median HbA1c 8.1% [7.0%–9.6%]), 1623 (65.0%) were classified as having advanced CKM syndrome (Table 1). Compared with those in non‐advanced stages, patients with advanced CKM syndrome were older, more likely to be current smokers and exhibited a more adverse cardiometabolic profile, characterised by longer diabetes duration, higher systolic blood pressure, BMI and HbA1c, along with lower eGFR. The use of insulin, antihypertensive agents and lipid‐lowering agents was also more prevalent (all p < 0.05; Table 1). TABLE 1Characteristics of participants.TotalNon‐advanced CKMAdvanced CKM p Participants, n 24978741623Sex, n (%)< 0.001Male1333 (53.4)351 (40.2)982 (60.5)Female1164 (46.6)523 (59.8)641 (39.5)Age, years67.0 (64.0, 72.0)64.0 (62.0, 67.0)69.0 (65.0, 73.0)< 0.001Diabetes duration, years15.0 (9.0, 21.0)14.0 (8.0, 20.0)16.0 (10.0, 22.0)< 0.001Systolic blood pressure, mmHg135.0 (125.0, 147.0)130.0 (120.0, 140.0)139.0 (129.0, 150.0)< 0.001Diastolic blood pressure, mmHg79.0 (72.0, 85.0)78.0 (71.0, 82.0)80.0 (72.0, 86.0)< 0.001Body mass index, kg/m2 24.1 (22.0, 26.1)23.4 (21.6, 25.6)24.2 (22.4, 26.4)< 0.001eGFR, mL/min/1.73 m2 87.9 (74.1, 94.7)92.8 (83.4, 96.8)84.6 (68.4, 92.4)< 0.001Total cholesterol, mmol/L4.3 (3.6, 5.2)4.5 (3.8, 5.3)4.2 (3.5, 5.1)< 0.001Triglycerides, mmol/L1.2 (0.9, 1.7)1.1 (0.8, 1.6)1.3 (0.9, 1.8)< 0.001HDL‐C, mmol/L1.1 (0.9, 1.3)1.2 (1.0, 1.4)1.1 (0.9, 1.3)< 0.001LDL‐C, mmol/L2.4 (1.8, 3.1)2.5 (2.0, 3.2)2.3 (1.8, 3.1)< 0.001HbA1c, %8.1 (7.0, 9.6)7.8 (6.8, 9.2)8.3 (7.2, 9.7)< 0.001HbA1c, mmol/mol65 (53, 81)62 (51, 77)67 (55, 83)< 0.001Current smoker, n (%)< 0.001No2083 (83.4)793 (90.7)1290 (79.5)Yes414 (16.6)81 (9.3)333 (20.5)Oral hypoglycemic drugs, n (%)0.059No use1039 (41.6)341 (39.0)698 (43.0)Use1458 (58.4)533 (61.0)925 (57.0)Metformin, n (%)875 (35.0)324 (37.1)551 (33.9)0.130Sulfonylureas, n (%)224 (9.0)91 (10.4)133 (8.2)0.076Thiazolidinediones, n (%)49 (2.0)18 (2.1)31 (1.9)0.916Glinides, n (%)82 (3.3)35 (4.0)47 (2.9)0.172α‐Glycosidase inhibitors, n (%)701 (28.1)262 (30.0)439 (27.0)0.132SGLT2 inhibitors, n (%)414 (16.6)137 (15.7)277 (17.1)0.403DPP‐4 inhibitors, n (%)369 (14.8)142 (16.2)227 (14.0)0.145GLP‐1 receptor agonist, n (%)0.498No use2425 (97.1)852 (97.5)1573 (96.9)Use72 (2.9)22 (2.5)50 (3.1)Insulin, n (%)< 0.001No use719 (28.8)328 (37.5)391 (24.1)Use1778 (71.2)546 (62.5)1232 (75.9)Anti‐hypertension agents, n (%)< 0.001No use1124 (45.0)604 (69.1)520 (32.0)Use1373 (55.0)270 (30.9)1103 (68.0)Lipid‐lowering agents, n (%)0.010No use617 (24.7)243 (27.8)374 (23.0)Use1880 (75.3)631 (72.2)1249 (77.0)Antiplatelet agents, n (%)< 0.001No use1643 (65.8)742 (84.9)901 (55.5)Use854 (34.2)132 (15.1)722 (44.5) Note: Data are presented as median (interquartile range) or number (percentage) unless otherwise indicated.Abbreviations: CKM, cardiovascular‐kidney‐metabolic; DPP‐4, dipeptidyl peptidase‐4; eGFR, estimated glomerular filtration rate; GLP‐1, glucagon‐like peptide‐1; HbA1c, glycated haemoglobin A1c; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; SGLT2, sodium‐glucose cotransporter2. Characteristics of participants. Note: Data are presented as median (interquartile range) or number (percentage) unless otherwise indicated. Abbreviations: CKM, cardiovascular‐kidney‐metabolic; DPP‐4, dipeptidyl peptidase‐4; eGFR, estimated glomerular filtration rate; GLP‐1, glucagon‐like peptide‐1; HbA1c, glycated haemoglobin A1c; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; SGLT2, sodium‐glucose cotransporter2. CGM Metrics and Advanced CKM Syndrome CGM‐derived glycemic profiles showed that patients with advanced CKM syndrome had a significantly lower TIR than those with non‐advanced CKM syndrome [70.0% (54.0%–84.0%) vs. 78.0% (62.0%–88.0%), p < 0.001; Figure 1]. In multivariable logistic regression adjusted for age, sex, diabetes duration and smoking status, both TIR and HbA1c were independently associated with advanced CKM syndrome. For each 1‐standard deviation decrease in TIR and increase in HbA1c, the ORs for advanced CKM syndrome were 1.28 (95% CI 1.16–1.42) and 1.17 (95% CI 1.07–1.30), respectively. Glycemic variability metrics (CV, SD and MAGE) did not show independent associations. Similar results were observed when glycemic metrics were analysed using clinically interpretable increments (Table S2). There was no significant difference between TIR and HbA1c in their overall discriminative performance for advanced CKM syndrome (p > 0.05). Glycemic profiles and associations with advanced CKM syndrome. (Left Panel) Glycemic metrics and the distribution of time spent in different glucose ranges in non‐advanced and advanced CKM groups. Data presented as median (interquartile range). (Right Panel) Adjusted odds ratios (ORs) for advanced CKM syndrome were expressed per 1‐standard deviation decrease in TIR and per 1‐standard deviation increase in HbA1c and the other CGM‐derived metrics. Models were adjusted for age, sex, diabetes duration and smoking status. Error bars indicate 95% confidence intervals. CGM, continuous glucose monitoring; CKM, cardiovascular‐kidney‐metabolic; CV, coefficient of variation; HbA1c, glycated haemoglobin A1c; MAGE, mean amplitude of glycemic excursions; SD, standard deviation; TAR, time above range; TBR, time below range; TIR, time in range. TIR and Advanced CKM Syndrome Restricted cubic spline analysis revealed a linear inverse relationship between TIR and the odds of advanced CKM syndrome (p for nonlinearity = 0.3938; Figure 2). Furthermore, the restricted cubic spline curve showed that when TIR was below approximately 72%, the odds of advanced CKM syndrome increased with decreasing TIR. Based on this pattern and clinical feasibility, a TIR of 70% was selected as a candidate target for comparison with the current guideline‐recommended target of 50%. Association of TIR with advanced CKM syndrome. (Left Panel) Restricted cubic spline analysis of TIR in relation to advanced CKM syndrome, with adjusted odds ratios (ORs) and 95% confidence intervals. Inset: Adjusted ORs according to categorised TIR levels. (Right Panel) Adjusted odds ratios for advanced CKM syndrome across TIR categories (≤ 50%, 50%–70% and > 70%), with TIR > 70% as the reference group. Total numbers, event counts and event prevalence shown for each category. Models were adjusted for sex, age, diabetes duration and smoking status. CI, confidence interval; CKM, cardiovascular‐kidney‐metabolic; OR, odds ratio; TIR, time in range. Exploring Achievable TIR Targets in Older Adults Within the CKM Framework Adopting a TIR target of > 70% yielded a significant continuous NRI for advanced CKM syndrome compared with the > 50% target (NRI = 0.1326, p < 0.01), while maintaining stable C‐statistics and IDI (Table S3). When stratified by TIR levels (> 70%, 50%–70% and ≤ 50%), the prevalence of advanced CKM syndrome increased progressively (58.8%, 70.2% and 75.2%, respectively; p for trend < 0.001). Compared to patients achieving TIR > 70%, those with TIR ≤ 50% had the highest odds (OR = 1.73, 95% CI 1.31–2.29). Of note, individuals in the TIR 50%–70% range, considered ‘at target’ by guidelines, still exhibited 40% increased odds of advanced CKM syndrome (OR = 1.40, 95% CI 1.12–1.75; Figure 2). Cumulative distribution plots and the proportions of participants achieving candidate TIR targets are presented in Figure 3. In the overall population, 82.3% of participants achieved a TIR of > 50%, whereas 53.5% achieved a TIR of > 70% (Figure 3A). Among participants with non‐advanced CKM syndrome, the proportions achieving TIR > 50% and > 70% were 87.4% and 62.9%, respectively. Corresponding proportions in participants with advanced CKM syndrome were 79.5% and 48.4% (Figure 3B). Cumulative distribution of the proportion meeting candidate TIR targets. Percentages of participants achieving candidate TIR targets (> 50% and > 70%) in the overall population (A) and stratified by non‐advanced and advanced CKM syndrome (B). CKM, cardiovascular‐kidney‐metabolic; TIR, time in range. For safety assessment, TIR was weakly correlated with TBR (r = 0.070, p < 0.001; Figure S2). Across TIR subgroups, the median TBR remained consistent at 0.0% (0.0%–1.0%). Among participants with TIR > 50%, the proportion achieving the clinical target for hypoglycemia exposure (TBR < 1%) remained stable at 67.0%–69.0%. Regression analyses further showed that higher TIR levels were not associated with an increased risk of hypoglycemia (Figure S3A). Similar findings were observed in analyses restricted to participants treated with insulin and/or sulfonylureas (Figure S3B) and when hypoglycemia was assessed using CGM‐defined episodes (Table S4). Sensitivity and Subgroup Analyses Subgroup analyses showed that the association between TIR and advanced CKM syndrome was generally consistent across sex, age, BMI, eGFR and HbA1c categories (all p for interaction > 0.05; Figure 4). In treatment‐related subgroup analyses, no significant interactions were found according to insulin use or SGLT2 inhibitor use. Although a nominal interaction was observed for GLP‐1 RA use (p for interaction = 0.030), the estimate among GLP‐1 RA users had a wide confidence interval. Subgroup analyses of the association between TIR and advanced CKM syndrome. Adjusted odds ratios (ORs) and 95% confidence intervals for advanced CKM syndrome associated with TIR ≤ 70% versus > 70% across predefined subgroups stratified by sex, age, body mass index, eGFR, HbA1c, insulin use, SGLT2 inhibitor use and GLP‐1 RA use. Total numbers and event counts are shown for each subgroup. p‐values for interaction were derived from multiplicative interaction terms in multivariable logistic regression models adjusted for age, sex, diabetes duration and smoking status. CI, confidence interval; CKM, cardiovascular‐kidney‐metabolic; eGFR, estimated glomerular filtration rate; GLP‐1 RA, glucagon‐like peptide‐1 receptor agonist; HbA1c, glycated haemoglobin A1c; OR, odds ratio; SGLT2, sodium‐glucose cotransporter 2; TIR, time in range. Medication‐adjusted sensitivity analyses are shown in Table S5. After additional adjustment for SGLT2 inhibitor and GLP‐1 RA use, participants with TIR 50%–70% continued to have higher odds of advanced CKM syndrome than those with TIR > 70% (OR = 1.45, 95% CI 1.16–1.82). Sensitivity analysis in participants aged ≥ 65 years (N = 1729) yielded similar results, with TIR remaining significantly associated with advanced CKM syndrome (for each 1‐standard deviation decrease: OR = 1.27, 95% CI 1.12–1.45). In this subgroup, TIR 50%–70% continued to be associated with higher odds compared to TIR > 70% (Table S6), while achieving TIR > 70% was not associated with an increased risk of hypoglycemia (p > 0.05). Discussion In this large‐scale study of older adults with type 2 diabetes, we explored the potential value of CGM‐derived TIR in evaluating multisystem cardiovascular–kidney–metabolic burden. TIR was associated with advanced CKM syndrome. Furthermore, when clinically relevant TIR thresholds were examined, participants with TIR levels of 50%–70%, a range exceeding the currently recommended target of > 50% for older adults, still had higher odds of advanced CKM syndrome. Higher TIR was not associated with increased exposure to hypoglycemia. These findings prompt further consideration of optimal TIR targets in this population. The CKM framework has paved the way for novel insights into the progressive interplay among metabolic, cardiovascular and renal dysfunction. However, it should not be viewed merely as a static clustering of comorbidities. Rather, metabolic dysregulation plays a central role in initiating CKM progression, whereas cardiovascular and renal injury reflect the cumulative downstream consequences of this pathophysiological process [18]. Accordingly, advanced CKM syndrome is regarded as a stage in which multisystem pathological damage has accumulated, as evidenced by consistent associations with long‐term adverse outcomes across several landmark cohorts [19, 20, 21]. In NHANES, advanced CKM syndrome was linked to significantly higher risks of all‐cause, cardiovascular and CKM‐related mortality compared with non‐advanced stages [22]. Similar findings were observed in the UK Biobank, where participants with CKM stages 3 and 4 had 54% and 130% higher risks of all‐cause mortality, respectively, than those at stage 0 [23]. Within this continuum of progressive injury, type 2 diabetes lies at an intermediate position, representing both a consequence of early metabolic risk factors (stage 1) and a critical link bridging to subclinical and overt cardiovascular and renal injury (stages 3 and 4). On this basis, the present study focused on advanced CKM syndrome among individuals with type 2 diabetes, a stage at which glycemic management targets are particularly relevant. Diabetes is highly prevalent in the aging population, with approximately one‐third of individuals aged 65 years or older affected [24]. Similarly, the prevalence of advanced CKM syndrome increases markedly with age. Data from NHANES indicate that advanced CKM syndrome affects 55.3% of older adults in the United States, substantially exceeding the prevalence observed in middle‐aged (10.7%) and younger populations (2.1%) [7]. Comparable findings have been reported in China, where the prevalence of advanced CKM syndrome among older adults reaches 50.1% [6]. This unique group faces challenges associated with the coexistence of multiple chronic conditions, as well as challenges arising from aging‐related frailty, rendering them susceptible to multiorgan injury even from a single metabolic disturbance [25, 26]. Nevertheless, older adults and individuals with multimorbidity are often excluded from clinical studies, resulting in considerable evidence gaps in individualised glycemic management for this population. Previous large randomised clinical trials have shown that intensive glycemic control (HbA1c < 6.0%–6.5%) failed to reduce cardiovascular events or all‐cause mortality and, in some cases, was linked to an increased risk of adverse outcomes. In the ACCORD trial, intensive therapy targeting near‐normal glycemia was associated with increased all‐cause mortality, raising particular concern for older adults [27]. Similarly, neither the ADVANCE nor the VADT trial demonstrated clear cardiovascular benefits of intensive glycemic control in older patients [28, 29]. However, these findings may partially stem from the inherent limitations of HbA1c, the traditional gold standard of glycemic assessment, which inadequately captures glycemic variability and hypoglycemia. In older adults, hypoglycemia can precipitate falls, cardiac arrhythmias and its clinical consequences may outweigh the long‐term harms of hyperglycemia in selected patients [30]. Guided by this risk–benefit balance, international CGM consensus recommendations since 2019 and long‐standing ADA guidelines have advocated a less stringent glycemic target for older adults, corresponding to a TIR > 50% (approximately equivalent to HbA1c < 8.0%) [31, 32]. However, this threshold is supported by limited direct evidence. With the widespread adoption of CGM, studies such as WISDM and MOBILE have demonstrated that CGM use in older adults can substantially increase TIR while reducing hypoglycemia [33, 34]. Against this backdrop, continued reliance on a TIR target of > 50%, derived from HbA1c‐based thresholds, may be overly conservative for selected older adults, potentially missing opportunities to delay vascular complications through higher TIR levels (e.g., > 70%). Evidence from Beck et al. has shown a strong inverse association between TIR and microvascular complication risk, with higher TIR associated with lower risks of retinopathy progression and microalbuminuria [35]. Advances in diabetes management, including multi‐target therapies (e.g., SGLT2 inhibitor and GLP‐1 RA) and CGM technology, have made higher TIR targets increasingly feasible. An analogous pattern was reported in the SPRINT trial, in which intensive blood pressure lowering (systolic blood pressure < 120 mmHg) conferred greater absolute benefit among individuals with advanced CKM stages [36]. To our knowledge, this is the first study to investigate CGM metrics within the CKM syndrome framework. From a clinical perspective, the association of lower TIR with prevalent advanced CKM syndrome in patients with type 2 diabetes offers a new perspective on the application of CGM in the context of multimorbidity. Traditionally, CGM has been regarded primarily as a tool for diabetes management, used to assess glycemic control and guide therapy. Within the CKM framework, which emphasises the continuum of metabolic, kidney and cardiovascular disease, the potential value of CGM may extend beyond glucose optimisation, as CGM‐derived metrics may serve as indicators of metabolic status along this multisystem disease continuum. This perspective is particularly relevant in older adults, in whom multimorbidity is common and overall disease burden may not be adequately captured by single‐complication assessments. By comparing candidate TIR thresholds, our findings also extend this observation to the consideration of TIR target setting in this heterogeneous population and provide a basis for prospective evaluation of individualised targets in selected older adults. Regarding glycemic variability, CV, SD and MAGE were not associated with advanced CKM syndrome. This may reflect the cumulative, stage‐defined nature of advanced CKM syndrome, which is likely more closely related to hyperglycemic exposure than to glycemic fluctuations. In line with this, measures of overall glycemic exposure have generally shown more consistent associations with vascular complications than glycemic variability [11, 12]. Several limitations should be acknowledged. First, given the cross‐sectional design, causal inferences cannot be established and the findings require confirmation in prospective cohorts. Second, although the CGM wear duration in this study was 7 days, shorter than the 14 days recommended by current guidelines, a 7‐day CGM assessment has been shown to remain reasonably reliable. Previous studies have shown that CGM‐derived indices demonstrate adequate reliability when assessed over shorter monitoring periods, with reliability coefficients exceeding 0.80 [37]. In Riddlesworth et al. the correlation (R 2) for TIR was 0.84 with 7 days of CGM data versus 0.88 with 14 days, relative to full 3‐month values [38]. Third, CGM was performed during hospitalisation, which may limit the generalisability of our findings to outpatient or community settings. Finally, the American Heart Association Predicting Risk of Cardiovascular Disease Events (PREVENT) risk assessment model used in this study was primarily developed from United States community‐based cohorts. Although it is widely used for CKM risk stratification, large‐scale validation in Chinese populations has yet to be fully established. In summary, this study showed an association between TIR and advanced CKM syndrome in older adults with type 2 diabetes. Our findings suggest that, alongside advances in glucose monitoring and therapy, consideration of higher TIR targets than currently recommended may be warranted in selected older adults. Moreover, this study highlights potential new directions for the use of CGM in populations with multimorbidity. Author Contributions J.L. and X.M. conceived and designed the study, contributed to the interpretation of the data and revision of the manuscript, have full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. H.S., J.N. and J.C. contributed to data collection, data analysis and manuscript preparation. J.Z., J.L. and X.M. contributed to interpretation of data and revision of the manuscript. W.Z. and Y.W. contributed to the conduction of the study and to data collection. All authors read and approved the final manuscript. Funding This work was funded by Noncommunicable Chronic Diseases‐National Science and Technology Major Project (2023ZD0518300), Shanghai Leading Talent Program of Eastern Talent Plan (LJ2024121), Shanghai Oriental Talent Program (Youth Project), Shenzhen Medical Research Fund (C2406002) and Sanming Project of Medicine in Shenzhen (SZSM202311019). Ethics Statement This study was approved by the Ethics Committee of Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine and was in accordance with the Declaration of Helsinki and its later amendments or comparable ethical standards. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Figure S1: Flow diagram of the study population. Figure S2: Association of TIR with hypoglycemia and hyperglycemia metrics. Figure S3: Association between TIR categories and hypoglycemia risk. Table S1: Definitions of CKM syndrome stages. Table S2: Associations of glycemic metrics with advanced CKM syndrome. Table S3: Association and discriminative performance of TIR thresholds and HbA1c for advanced CKM syndrome. Table S4: Presence of CGM‐defined hypoglycemic episodes across TIR categories. Table S5: Association between TIR and advanced CKM syndrome with additional adjustment for medication use. Table S6: Association of TIR with the advanced CKM syndrome in the population aged ≥ 65 years (N = 1729). Acknowledgements We would like to thank all of the involved clinicians, nurses and technicians for dedicating their time and skills to the completion of this study. We would like to thank all participants for their dedication to data collection and laboratory measurements. Su H., Ni J., Cai J., et al., “Association Between Time in Range and Advanced Cardiovascular‐Kidney‐Metabolic Syndrome in Older Adults With Type 2 Diabetes,” Diabetes, Obesity and Metabolism 28, no. 10 (2026): 9265–9274, 10.1111/dom.71143. Handling Editor: Richard Donnelly Contributor Information Jingyi Lu, Email: jingyi.lu@shsmu.edu.cn. Xiaojing Ma, Email: maxiaojing@sjtu.edu.cn. Data Availability Statement Restrictions apply to the availability of data generated or analysed during this study to preserve patient confidentiality or because they were used under license. Data are, however, available from the authors upon reasonable request. References Associated Data Supplementary Materials Figure S1: Flow diagram of the study population. Figure S2: Association of TIR with hypoglycemia and hyperglycemia metrics. Figure S3: Association between TIR categories and hypoglycemia risk. Table S1: Definitions of CKM syndrome stages. Table S2: Associations of glycemic metrics with advanced CKM syndrome. Table S3: Association and discriminative performance of TIR thresholds and HbA1c for advanced CKM syndrome. Table S4: Presence of CGM‐defined hypoglycemic episodes across TIR categories. Table S5: Association between TIR and advanced CKM syndrome with additional adjustment for medication use. Table S6: Association of TIR with the advanced CKM syndrome in the population aged ≥ 65 years (N = 1729). Data Availability Statement Restrictions apply to the availability of data generated or analysed during this study to preserve patient confidentiality or because they were used under license. Data are, however, available from the authors upon reasonable request.